Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 1

Interventions

Nivolumab 25pembrolizumab 24Specimen Handling 17Ipilimumab 16Magnetic Resonance Spectroscopy 12Opdualag 7CTLA-4 Antigen 7Biopsy 6trametinib 5relatlimab 5dabrafenib 4binimetinib 4Paclitaxel 4Cyclophosphamide 4fludarabine 3capivasertib 3atezolizumab 3aldesleukin 3Taxes 3Standard of Care 3Pemetrexed 3Introns 3Interferon alpha-2 3Gemcitabine 3Carboplatin 3Blood Specimen Collection 3ulixertinib 2tislelizumab 2sargramostim 2omipalisib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × 1-methyltryptophan × 30 days × Clear all
NCT02073123 2026-05-29

Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma

Lumos Pharma

Phase 1/2 Completed
131 enrolled 23 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡